Aligos Therapeutics, Inc. Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs
Aligos Therapeutics, Inc. (ALGS) reported Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs of $3.66 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts · last filed 2026-03-05
- Aligos Therapeutics, Inc. adjustments to additional paid in capital, stock issued, issuance costs for fiscal 2025 was $3.66M.
| Period end | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 12 month |
|---|---|
| 2025-12-31 | $3.66M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |